MAZ promotes thyroid cancer progression by driving transcriptional reprogram and enhancing ERK1/2 activation
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.217201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Jiajia Zeng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Provincial Key Laboratory of Precision Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, C…. Hauptthemen laut MEDLINE: Cell Proliferation, Disease Progression, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Major Scientific and Technological Innovation Project of Shandong Province.
Abstract (Originalsprache)
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancies worldwide. Oncogenic transcription factors (TFs) drive transcriptional reprogramming and tumorigenesis. The myc-associated zinc finger protein (MAZ) is one of the Myc family TFs. The role of MAZ in PTC pathogenesis is still largely unknown. Here, we report that MAZ profoundly promotes proliferation of PTC cells ex vivo and in vivo through activating MAPK signaling. We firstly profiled gene expression of PTC cells after silencing of MAZ. BRAF, KRAS and LOC547 were identified as important target genes of TF MAZ. In particular, TF MAZ bound to the promoters of BRAF or KRAS and significantly increased their transcription and expression levels. Meanwhile, MAZ could noticeably elevate LOC547 transcription and expression as a TF. High levels of LOC547 relocated ACTN4 protein from the nucleus to the cytosol, improved protein-protein interactions between ACTN4 and EGFR in the cytosol, enhanced ERK1/2 phosphorylation, activated the MAPK signaling and, thus, promoted PTC progression. Our data identify a previously underappreciated MAZ-controlled transcriptional reprogram and ERK1/2 activation via BRAF, KRAS and LOC547. Our data illustrate that activation of the MAZ-controlled axis promotes thyroid tumorigenesis. These insights would advance our knowledge of the role of TFs in cancer development and highlight the potential of TFs as future targets for treatments against cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shandong Provincial Key Laboratory of Precision Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, China; School of Life Sciences, Shandong First Medical University and S…
- Shandong Provincial Key Laboratory of Precision Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, China.
- Shandong University Cancer Center, Jinan, Shandong Province, China.
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China; Jiangsu Key Lab of Cancer Biomarkers…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Major Scientific and Technological Innovation Project of Shandong Province
- Taishan Scholar Project of Shandong Province
Zitieren
APA
Zeng, J., Zhang, L., Huang, L., Yu, X., Han, L., Zheng, Y., Wang, T., Zhang, N., & Yang, M. (2024). MAZ promotes thyroid cancer progression by driving transcriptional reprogram and enhancing ERK1/2 activation. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217201
Vancouver
Zeng J, Zhang L, Huang L, Yu X, Han L, Zheng Y, et al. MAZ promotes thyroid cancer progression by driving transcriptional reprogram and enhancing ERK1/2 activation. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217201
BibTeX
@article{Zeng2024,
author = {Zeng, Jiajia and Zhang, Long and Huang, Linying and Yu, Xinyuan and Han, Linyu and Zheng, Yanxiu and Wang, Teng and Zhang, Nasha and Yang, Ming},
title = {MAZ promotes thyroid cancer progression by driving transcriptional reprogram and enhancing ERK1/2 activation},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.217201}
}
EUVIMED